astaxanthin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“Following ASX treatment (30 mg/kg or 60 mg/kg), ALT and AST decreased in a dose-dependent manner.”
Quoted verbatim from Astaxanthin Pretreatment Attenuates Hepatic Ischemia Reperfusion-Induced Apoptosis and Autophagy via the ROS/MAPK Pathway in Mice.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 30 mg/kg or 60 mg/kg for 14 days before ischemia reperfusion
- Population
- Mice with hepatic ischemia reperfusion injury, pretreated with astaxanthin 30 or 60 mg/kg for 14 days, compared with the untreated ischemia reperfusion group
Astaxanthin Pretreatment Attenuates Hepatic Ischemia Reperfusion-Induced Apoptosis and Autophagy via the ROS/MAPK Pathway in Mice.2015PMID:26023842Permalink
Keep reading
- Everything the graph holds on astaxanthin
- Every compound studied against Alanine aminotransferase
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PCYTRBY7W5VHARRGBY9NBZ